(Updated - July 18, 2017 6:42 AM EDT)

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $1.83, $0.03 better than the analyst estimate of $1.80. Revenue for the quarter came in at $18.8 billion versus the consensus estimate of $18.97 billion.

GUIDANCE:

Johnson & Johnson sees FY2017 EPS of $7.12-$7.22, versus the consensus of $7.10.

• The Company increased its sales guidance for the full-year 2017 to $75.8 billion to $76.1 billion ( vs consensus of $75.67 billion).

"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA™ as well as the submission and approval of several key line extensions," said Alex Gorsky, Chairman and Chief Executive Officer. "The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson Family of Companies. Together with all of our businesses, we will continue to transform the lives of patients around the world."

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.